{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:25:42Z","timestamp":1783974342002,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016237","name":"Armauer Hansen Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016237","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007941","name":"Addis Ababa University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Retrovirology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The development of pretreatment drug resistance (PDR) is becoming an obstacle to the success of antiretroviral therapy (ART). Besides, data from developing settings including Ethiopia is still limited. Therefore, this study was aimed to assess HIV-1 genetic diversity and PDR mutations among ART-naive recently diagnosed HIV-1 infected individuals in Addis Ababa, Ethiopia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Institutional based cross-sectional study was conducted from June to December 2018 in Addis Ababa among ART-naive recently diagnosed individuals. Partial HIV-1 pol region covering the entire protease (PR) and partial reverse transcriptase (RT) regions of 51 samples were amplified and sequenced using an in-house assay. Drug resistance mutations were examined using calibrated population resistance (CPR) tool version 6.0 from the Stanford HIV drug resistance database and the International Antiviral Society-USA (IAS-USA) 2019 mutation list.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>According to both algorithms used, 9.8% (5\/51) of analyzed samples had at least one PDR Mutation. PDR mutations to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) were the most frequently detected (7.8% and 9.8%, according to the CPR tool and IAS-USA algorithm, respectively). The most frequently observed NNRTIs-associated mutations common to both algorithms were K103N (2%), Y188L (2%), K101E (2%), and V106A (2%), while E138A (2%) was observed according to IAS-USA only. Y115F and M184V (mutations that confer resistance to NRTIs) dual mutations were detected according to both criteria in a single study participant (2%). PDR mutation to protease inhibitors was found to be low (only G73S; 2% according to the CPR tool). Phylogenetic analysis showed that 98% (50\/51) of the study participants were infected with HIV-1C virus while one individual (2%) was infected with HIV-1A1 virus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study showed an increased level of PDR and persistence HIV-1C clade homogeneity after 15\u00a0years of the rollout of ART and 3 decades of HIV-1C circulation in Ethiopia, respectively. Therefore, we recommend routine baseline genotypic drug resistance testing for all newly diagnosed HIV infected patients before initiating treatment. This will aid the selection of appropriate therapy in achieving the 90% of patients having an undetectable viral load in consonance with the UN target.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12977-020-00542-0","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T15:04:28Z","timestamp":1601391868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1 infected individuals in Ethiopia"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7909-7719","authenticated-orcid":false,"given":"Mulugeta","family":"Kiros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawit Hailu","family":"Alemayehu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Geberekidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adane","family":"Mihret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woldaregay Erku","family":"Abegaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andargachew","family":"Mulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"542_CR1","unstructured":"The Joint United Nations Programme on HIV\/AIDS (UNAIDS). FACT SHEET\u2014GLOBAL AIDS UPDATE 2019. 2019."},{"key":"542_CR2","unstructured":"UNAIDS (Joint United Nations Program on HIV\/AIDS). UNAIDS DATA 2017."},{"key":"542_CR3","unstructured":"The Joint United Nations Programme on HIV\/AIDS (UNAIDS). UNAIDS Data. 2019."},{"issue":"1","key":"542_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12963-017-0145-1","volume":"15","author":"A Misganaw","year":"2017","unstructured":"Misganaw A, Haregu TN, Deribe K, Tessema GA, Deribew A, Melaku YA, et al. National mortality burden due to communicable, non-communicable, and other diseases in Ethiopia, 1990\u20132015: findings from the Global Burden of Disease Study 2015. Popul Health Metrics. 2017;15(1):29.","journal-title":"Popul Health Metrics."},{"key":"542_CR5","unstructured":"World Health Organization (WHO). Ethiopia HIV Country Profile 2017 2019 http:\/\/cfs.hivci.org\/country-factsheet.html#."},{"key":"542_CR6","unstructured":"Federal HIV\/AIDS Prevention and Control Office. HIV Prevention in Ethiopia National Road Map\u00a02018\u20132020. 2018."},{"issue":"5","key":"542_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.coph.2010.04.011","volume":"10","author":"E De Clercq","year":"2010","unstructured":"De Clercq E. Antiretroviral drugs. Curr Opin Pharmacol. 2010;10(5):507\u201315.","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"542_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cmi.2018.09.025","volume":"25","author":"M Stecher","year":"2019","unstructured":"Stecher M, Chaillon A, Eis-Hubinger AM, Lehmann C, Fatkenheuer G, Wasmuth JC, et al. Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. Clin Microbiol Infect. 2019;25(2):253.","journal-title":"Clin Microbiol Infect"},{"key":"542_CR9","doi-asserted-by":"publisher","first-page":"e4848","DOI":"10.7717\/peerj.4848","volume":"6","author":"M Zazzi","year":"2018","unstructured":"Zazzi M, Hu H, Prosperi M. The global burden of HIV-1 drug resistance in the past 20 years. PeerJ. 2018;6:e4848.","journal-title":"PeerJ."},{"issue":"2","key":"542_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/QAI.0000000000000831","volume":"71","author":"T Panichsillapakit","year":"2016","unstructured":"Panichsillapakit T, Smith DM, Wertheim JO, Richman DD, Little SJ, Mehta SR. Prevalence of transmitted HIV drug resistance among recently infected persons in San Diego, CA 1996\u20132013. J Acquir Immune Defic Syndr. 2016;71(2):228\u201336.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"542_CR11","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1093\/jac\/dkz134","volume":"74","author":"GA Yendewa","year":"2019","unstructured":"Yendewa GA, Sahr F, Lakoh S, Ruiz M, Patino L, Tabernilla A, et al. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone. The Journal of antimicrobial chemotherapy. 2019;74(7):2024\u20139.","journal-title":"The Journal of antimicrobial chemotherapy."},{"key":"542_CR12","unstructured":"World Health Organization (WHO). HIV DRUG RESISTANCE REPORT 2019. Geneva, Switzerland: World Health Organization; 2019 (WHO\/CDS\/HIV\/19.21). Report No.: Licence: CC BY-NC-SA 3.0 IGO."},{"issue":"6","key":"542_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7883\/yoken.JJID.2016.512","volume":"70","author":"HT Do","year":"2017","unstructured":"Do HT, Nguyen DT, Nguyen LAT, Do DH, Le HX, Trinh XMT, et al. An alarmingly high proportion of HIV-1 isolates carrying mutations corresponding to resistance to antiretroviral drugs among HIV-positive High-Risk Groups in Central Vietnam: a Substudy of the National Sentinel Survey. Jpn J Infect Dis. 2017;70(6):621\u20137.","journal-title":"Jpn J Infect Dis."},{"key":"542_CR14","unstructured":"Federal Ministry of Health (FMOH). National guidelines for comprehensive HIV prevention, care and treatment. 2018."},{"issue":"10","key":"542_CR15","doi-asserted-by":"publisher","first-page":"e0205446","DOI":"10.1371\/journal.pone.0205446","volume":"13","author":"DA Arimide","year":"2018","unstructured":"Arimide DA, Abebe A, Kebede Y, Adugna F, Tilahun T, Kassa D, et al. HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003\u20132013. PLoS ONE. 2018;13(10):e0205446.","journal-title":"PLoS ONE"},{"issue":"6","key":"542_CR16","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/jmv.24110","volume":"87","author":"K Huruy","year":"2015","unstructured":"Huruy K, Maier M, Mulu A, Liebert UG. Limited increase in primary HIV-1C drug resistance mutations in treatment naive individuals in Ethiopia. J Med Virol. 2015;87(6):978\u201384.","journal-title":"J Med Virol"},{"issue":"1","key":"542_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2334-14-158","volume":"14","author":"A Mulu","year":"2014","unstructured":"Mulu A, Lange T, Liebert UG, Maier M. Clade homogeneity and Pol gene polymorphisms in chronically HIV-1 infected antiretroviral treatment naive patients after the roll out of ART in Ethiopia. BMC Infect Dis. 2014;14(1):158.","journal-title":"BMC Infect Dis"},{"key":"542_CR18","unstructured":"Ethiopian Public Health Insitute. HIV Drug Resistance Early Warning Indicators Survey in Ethiopia. 2013\/14."},{"key":"542_CR19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/135965350801302S01","volume":"13","author":"WE Abegaz","year":"2008","unstructured":"Abegaz WE, Grossman Z, Wolday D, Ram D, Kaplan J, Sibide K, et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antiviral Ther. 2008;13:89.","journal-title":"Antiviral Ther."},{"issue":"10","key":"542_CR20","doi-asserted-by":"publisher","first-page":"e111042","DOI":"10.1371\/journal.pone.0111042","volume":"9","author":"H Ekici","year":"2014","unstructured":"Ekici H, Amogne W, Aderaye G, Lindquist L, Sonnerborg A, Abdurahman S. Minority drug-resistant HIV-1 variants in treatment naive East-African and Caucasian patients detected by allele-specific real-time PCR. PLoS ONE. 2014;9(10):e111042.","journal-title":"PLoS ONE"},{"key":"542_CR21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350801302S04","volume":"13","author":"DE Bennett","year":"2008","unstructured":"Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antiviral Ther. 2008;13:25.","journal-title":"Antiviral Ther."},{"key":"542_CR22","first-page":"1525646","volume":"2019","author":"CK Chauhan","year":"2019","unstructured":"Chauhan CK, Lakshmi PVM, Sagar V, Sharma A, Arora SK, Kumar R. Primary HIV drug resistance among recently infected cases of HIV in North-West India. AIDS Res Treat. 2019;2019:1525646.","journal-title":"AIDS Res Treat."},{"issue":"5","key":"542_CR23","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1089\/aid.2015.0380","volume":"32","author":"W Amogne","year":"2016","unstructured":"Amogne W, Bontell I, Grossmann S, Aderaye G, Lindquist L, S\u00f6nnerborg A, et al. Phylogenetic analysis of Ethiopian HIV-1 subtype C near full-length genomes reveals high intrasubtype diversity and a strong geographical cluster. AIDS Res Hum Retroviruses. 2016;32(5):471\u20134.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"542_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1590\/1516-3180.2017.0233011017","volume":"136","author":"ATM Pimenta","year":"2018","unstructured":"Pimenta ATM, Correa IA, Melli P, Abduch R, Duarte G, Couto-Fernandez JC, et al. HIV-1 genetic diversity and resistance to antiretroviral drugs among pregnant women in Ribeirao Preto (SP), Brazil Cross-sectional study. Sao Paulo Med J. 2018;136(2):129\u201335.","journal-title":"Sao Paulo Med J"},{"issue":"8","key":"542_CR25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1089\/aid.2019.0022","volume":"35","author":"M Nesakumar","year":"2019","unstructured":"Nesakumar M, Haribabu H, Cheedarla N, Karunaianantham R, Kailasam N, Sathyamoorthy P, et al. Transmitted HIV-1 drug resistance in a treatment naive cohort of recently infected individuals from Chennai, India. AIDS Res Hum Retroviruses. 2019;35(8):775\u20139.","journal-title":"AIDS Res Hum Retroviruses."},{"key":"542_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fmicb.2019.00020","volume":"10","author":"TSO Tanaka","year":"2019","unstructured":"Tanaka TSO, Leite TF, Freitas SZ, Cesar GA, de Rezende GR, Lindenberg ASC, et al. HIV-1 molecular epidemiology, transmission clusters and transmitted drug resistance mutations in Central Brazil. Front Microbiol. 2019;10:20.","journal-title":"Front Microbiol."},{"issue":"3","key":"542_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00705-018-04122-8","volume":"164","author":"LPO Coelho","year":"2019","unstructured":"Coelho LPO, Matsuda EM, Nogueira RS, de Moraes MJ, Jamal LF, Madruga JVR, et al. Prevalence of HIV-1 transmitted drug resistance and viral suppression among recently diagnosed adults in Sao Paulo, Brazil. Arch Virol. 2019;164(3):699\u2013706.","journal-title":"Arch Virol."},{"issue":"1","key":"542_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12981-019-0219-1","volume":"16","author":"LD Bahls","year":"2019","unstructured":"Bahls LD, Canezin PH, Reiche EMV, Fernandez JCC, Dias JRC, Meneguetti VAF, et al. Moderate prevalence of HIV-1 transmitted drug resistance mutations in southern Brazil. AIDS Res Ther. 2019;16(1):4.","journal-title":"AIDS Res Ther."},{"issue":"3","key":"542_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1017\/S0950268817003016","volume":"146","author":"YX Song","year":"2018","unstructured":"Song YX, Xin RL, Li ZC, Yu HW, Lun WH, Ye J, et al. Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing. Epidemiol Infect. 2018;146(3):339\u201344.","journal-title":"Epidemiol Infect"},{"issue":"6","key":"542_CR30","first-page":"1477","volume":"162","author":"R Vahabpour","year":"2017","unstructured":"Vahabpour R, Bokharaei-Salim F, Kalantari S, Garshasbi S, Monavari SH, Esghaei M, et al. HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals. Adv Virol. 2017;162(6):1477\u201385.","journal-title":"Adv Virol"},{"issue":"1","key":"542_CR31","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.1038\/s41598-018-25888-6","volume":"8","author":"NF Telele","year":"2018","unstructured":"Telele NF, Kalu AW, Gebre-Selassie S, Fekade D, Abdurahman S, Marrone G, et al. Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing. Sci Rep. 2018;8(1):7556.","journal-title":"Sci Rep."},{"issue":"4","key":"542_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1089\/aid.2006.0270","volume":"23","author":"A Kassu","year":"2007","unstructured":"Kassu A, Fujino M, Matsuda M, Nishizawa M, Ota F, Sugiura W. Molecular epidemiology of HIV type 1 in treatment-naive patients in north Ethiopia. AIDS Res Hum Retroviruses. 2007;23(4):564\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"542_CR33","unstructured":"World Health Organization (WHO). The HIV drug resistance report. Geneva: Switherland World Health Organization; 2017. Report No.: CC BY-NC-SA 3.0 IGO."},{"issue":"01","key":"542_CR34","doi-asserted-by":"publisher","first-page":"079","DOI":"10.3855\/jidc.3480","volume":"8","author":"M Azam","year":"2014","unstructured":"Azam M, Malik A, Rizvi M, Rai A. Zero prevalence of primary drug resistance-associated mutations to protease inhibitors in HIV-1 drug-naive patients in and around Aligarh, India. J Infect Dev Ctries. 2014;8(01):079\u201385.","journal-title":"J Infect Dev Ctries."}],"container-title":["Retrovirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-020-00542-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12977-020-00542-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-020-00542-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T04:37:56Z","timestamp":1669005476000},"score":1,"resource":{"primary":{"URL":"https:\/\/retrovirology.biomedcentral.com\/articles\/10.1186\/s12977-020-00542-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1186\/s12977-020-00542-0","relation":{},"ISSN":["1742-4690"],"issn-type":[{"value":"1742-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"25 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from Addis Ababa University, College of health sciences, department of Medical Microbiology, Immunology and Parasitology research and ethical review committee (DRERC) (Reference Number: DERC\/\/17\/18\/02-H), and Armauer Hansen Research Institute (AHRI)\/All Africa Leprosy Rehabilitation and Training Center ethical review committee (Protocol Number: PO16\/18). Written informed consent was obtained from the study participants before including them to the study. Samples were coded to keep the confidentiality of the study participants\u2019 personal information.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}